Skyrizi represents a breakthrough in treating inflammatory conditions, offering healthcare providers a structured dosing schedule and versatile indications. With options for patient self-administration and a focus on safety, Skyrizi enhances treatment flexibility and patient satisfaction. Explore how this innovative therapy can optimize outcomes for those managing Crohn’s disease and other inflammatory disorders.
Understanding Skyrizi Prescribing for Healthcare Providers
Skyrizi, an IL-23 inhibitor developed by AbbVie, is a significant advancement in the treatment of various inflammatory conditions, including moderately to severely active Crohn’s disease in adults. It offers a structured dosing schedule that allows for patient self-administration after appropriate training (source). The initial treatment phase involves three intravenous (IV) infusions of 600 mg each, administered over at least one hour. This is followed by maintenance doses through subcutaneous (SC) injections every eight weeks, which can be administered at home or in a healthcare setting (source).
Dosage Forms and Administration
Skyrizi is available in several dosage forms, including a 600 mg/10 mL single-dose vial for IV infusion and a 180 mg/1.2 mL or 360 mg/2.4 mL single-dose prefilled cartridge for SC injection using an on-body injector (OBI). The OBI is designed for ease of use, featuring a compact size, hands-free operation, a hidden needle, and audio-visual cues to notify patients when the full dose has been delivered. This design allows patients to engage in moderate physical activities during administration (source).
Safety Considerations and Side Effects
Healthcare providers must be aware of important safety considerations when prescribing Skyrizi. These include the risk of infections, hypersensitivity reactions, and potential hepatotoxicity. Patients should be evaluated for tuberculosis (TB) before starting treatment, and live vaccines should be avoided during therapy (source). Common adverse reactions in Crohn’s disease include upper respiratory infections, headache, arthralgia, abdominal pain, and injection site reactions. Lipid elevations have also been observed in patients treated with Skyrizi (source).
Indications and Versatility
Skyrizi is not only indicated for Crohn’s disease but also for the treatment of moderate to severe plaque psoriasis, active psoriatic arthritis, and moderately to severely active ulcerative colitis in adults. This versatility makes it a valuable option for healthcare providers treating various inflammatory conditions (source).
Patient Experience and Training
Patients have reported positive experiences with the Skyrizi OBI, citing ease of use and satisfaction in studies using the Self-Injection Assessment Questionnaire (SIAQ). Training from healthcare professionals is essential for effective self-administration, ensuring that patients are comfortable and confident in managing their treatment at home (source).
Why You Should Learn More About Skyrizi Prescribing Today
Understanding the prescribing information for Skyrizi is crucial for healthcare providers managing patients with inflammatory conditions. Its structured dosing schedule, versatile indications, and patient-friendly administration options make it a valuable treatment option. By staying informed about the latest safety considerations and patient experiences, healthcare providers can ensure optimal outcomes for their patients. Skyrizi’s ability to be self-administered after proper training offers convenience and flexibility, enhancing patient adherence and satisfaction. As the landscape of treatment options continues to evolve, Skyrizi stands out as a significant advancement in managing inflammatory diseases.